Skip to main content

Table 3 In-hospital management in tertiary care hospitals

From: Improved treatment and prognosis after acute myocardial infarction in Estonia: cross-sectional study from a high risk country

 

Year 2001

Year 2007

Year 2011

P value for trend

n = 210

n = 327

n = 302

%

%

%

Medications

    

 Aspirin

87.1

94.2

94.4

0.003

 P2Y12-receptor inhibitors

17.1

61.5

70.5

<0.001

 Anticoagulants

89.0

93.0

92.7

0.133

 Glycoprotein IIb/IIIa inh.

12.4

38.8

29.1

<0.001

 Betablockers

79.5

82.6

82.1

0.452

 Nitrates

92.4

78.9

76.2

<0.001

 ACEi/ARB

70.5

74.9

81.1

0.006

 Statins

26.7

67.9

77.2

<0.001

Cardiac catheterization

35.7

78.6

80.8

<0.001

Revascularization

27.6

64.2

73.5

<0.001

 PCI

22.4

61.5

67.9

<0.001

 CABG

5.2

3.7

6.0

0.722

Echocardiography

81.9

85.3

88.4

0.044

Treatment for STEMI

n = 130

n = 162

n = 160

 

Reperfusion for STEMI

42.3

64.2

63.1

<0.001

 Thrombolysis

35.4

7.4

0.6

<0.001

 Primary PCI

6.9

56.8

62.5

<0.001

Treatment for NSTEMI

n = 80

n = 165

n = 142

 

 PCI

18.8

47.9

53.5

<0.001

 CABG

7.5

3.6

9.2

0.56

  1. Anticoagulants – low molecular weight heparins/unfractionated heparin/ fondaparinux, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, P2Y12-receptor inhibitors – ticlopidine/clopidogrel/ticagrelol, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, STEMI ST- segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction